Gh Research Plc (GHRS) - News Archive

Showing 3 of 3 results.

GH Research PLC Raises $150 Million in Public Offering, Poised to Transform Depression Treatment Market

In a significant financial maneuver, Dublin-based GH Research PLC, a clinical-stage biopharmaceutical company listed on Nasdaq as GHRS, has announced the pricing of its underwritten public offering in the United States....

Feb 5, 2025 • Major Pharmaceutical Preparations Industry Stock Market Announcement biotechnology

GH Research PLC Embarks on $150 Million U.S. Public Offering to Propel Depression Treatment Innovations,

GH Research PLC Announces Ambitious $150 Million Public Offering to Accelerate Depression Treatment ResearchDublin-based clinical-stage biopharmaceutical innovator GH Research PLC has announced an underwritten public of...

Feb 3, 2025 • Major Pharmaceutical Preparations Industry Shares biotechnology

GH Research Receives European Patent for Groundbreaking Treatment of Depression with Mebufotenin (5-MeO-DMT) and Salt Products

GH Research Receives European Patent for Mebufotenin (5-MeO-DMT) and Salt Products in the Treatment of Major Depressive Disorder and Treatment-Resistant DepressionDUBLIN, Ireland, Jan. 18, 2024 - GH Research PLC (Nasdaq...

Jan 18, 2024 • Major Pharmaceutical Preparations Industry Product Service News biotechnology